产品号 #19849_C
免疫阴性选择细胞分离试剂盒
New format, same high quality! You may notice that your kit contents and packaging look slightly different from previous orders. We are currently updating the format of select EasySep™ Mouse kits to include a Mouse FcR blocker instead of Normal Rat Serum. With this change, all components will now be shipped in a single package, while providing the same cell isolation performance as before.
Products for Your Protocol
To see all required products for your protocol, please consult the Protocols and Documentation.
-
EasySep™ BufferCell separation buffer
概述
EasySep™小鼠/人嵌合体分离试剂盒旨在通过负选择从人异种移植受体小鼠的骨髓、脾脏或外周血中高度富集人细胞。不需要的细胞是针对小鼠造血细胞和链霉亲和素包被磁颗粒的生物素化抗体去除的目标。使用EasySep™磁铁分离标记细胞，不使用色谱柱。所需的细胞被倒进一个新的管中。
本产品可用于代替StemSep™小鼠/人嵌合体富集试剂盒（目录#13068），更快，更容易的细胞分离。
Magnet Compatibility
• EasySep™ Magnet (Catalog #18000)
• “The Big Easy” EasySep™ Magnet (Catalog #18001)
• EasyEights™ EasySep™ Magnet (Catalog #18103)
• EasyPlate™ EasySep™ Magnet (Catalog #18102)
Subtype
Cell Isolation Kits
Species
Mouse
Sample Source
Bone Marrow, Spleen, Whole Blood
Selection Method
Negative
Application
Cell Isolation
Brand
EasySep
Area of Interest
Cancer, Immunology
Subtype
Cell Isolation Kits
Species
Mouse
Sample Source
Bone Marrow, Spleen, Whole Blood
Selection Method
Negative
Application
Cell Isolation
Brand
EasySep
Area of Interest
Cancer, Immunology
Data Figures
Protocols and Documentation
Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.
Resources and Publications
Educational Materials (10)
Frequently Asked Questions
Publications (2)
Despite mutation acquisition in hematopoietic stem cells, JMML-propagating cells are not always restricted to this compartment. Leukemia 2020 jun
Abstract
Juvenile myelomonocytic leukemia (JMML) is a rare aggressive myelodysplastic/myeloproliferative neoplasm of early childhood, initiated by RAS-activating mutations. Genomic analyses have recently described JMML mutational landscape; however, the nature of JMML-propagating cells (JMML-PCs) and the clonal architecture of the disease remained until now elusive. Combining genomic (exome, RNA-seq), Colony forming assay and xenograft studies, we detect the presence of JMML-PCs that faithfully reproduce JMML features including the complex/nonlinear organization of dominant/minor clones, both at diagnosis and relapse. Further integrated analysis also reveals that although the mutations are acquired in hematopoietic stem cells, JMML-PCs are not always restricted to this compartment, highlighting the heterogeneity of the disease during the initiation steps. We show that the hematopoietic stem/progenitor cell phenotype is globally maintained in JMML despite overexpression of CD90/THY-1 in a subset of patients. This study shed new lights into the ontogeny of JMML, and the identity of JMML-PCs, and provides robust models to monitor the disease and test novel therapeutic approaches.
Genetically Engineered Cell-Derived Nanoparticles for Targeted Breast Cancer Immunotherapy. Molecular therapy : the journal of the American Society of Gene Therapy 2019 nov
Abstract
Exosomes are nanosized membranous vesicles secreted by a variety of cells. Due to their unique and pharmacologically important properties, cell-derived exosome nanoparticles have drawn significant interest for drug development. By genetically modifying exosomes with two distinct types of surface-displayed monoclonal antibodies, we have developed an exosome platform termed synthetic multivalent antibodies retargeted exosome (SMART-Exo) for controlling cellular immunity. Here, we apply this approach to human epidermal growth factor receptor 2 (HER2)-expressing breast cancer by engineering exosomes through genetic display of both anti-human CD3 and anti-human HER2 antibodies, resulting in SMART-Exos dually targeting T cell CD3 and breast cancer-associated HER2 receptors. By redirecting and activating cytotoxic T cells toward attacking HER2-expressing breast cancer cells, the designed SMART-Exos exhibited highly potent and specific anti-tumor activity both in vitro and in vivo. This work demonstrates preclinical feasibility of utilizing endogenous exosomes for targeted breast cancer immunotherapy and the SMART-Exos as a broadly applicable platform technology for the development of next-generation immuno-nanomedicines.
更多信息
| Species | Mouse |
|---|---|
| Magnet Compatibility | • EasySep™ Magnet (Catalog #18000) • “The Big Easy” EasySep™ Magnet (Catalog #18001) • EasyEights™ EasySep™ Magnet (Catalog #18103) • EasyPlate™ EasySep™ Magnet (Catalog #18102) |
| Sample Source | Bone Marrow, Spleen, Whole Blood |
| Selection Method | Negative |
标记抗体
-
抗小鼠CD45R抗体，克隆RA3-6B2大鼠抗人、小鼠、猫CD45R单克隆抗体（B220）
-
抗小鼠TER119抗体，克隆TER-119抗小鼠TER119的大鼠（WI）单克隆IgG2b抗体
-
抗人CD45抗体，克隆HI30小鼠抗人、黑猩猩CD45单克隆IgG1抗体
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.
